Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study
Previous
Previous
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with HR-NBL (HR-NBL1/SIOPEN ph 3 trial)
Next
Next